{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T01:44:31Z","timestamp":1720662271338},"reference-count":88,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":5875,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1002\/clc.4960221608","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T06:15:32Z","timestamp":1247724932000},"page":"44-53","source":"Crossref","is-referenced-by-count":7,"special_numbering":"supplement S4","title":["Future directions in thrombolysis"],"prefix":"10.1002","volume":"22","author":[{"given":"James T.","family":"Willerson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Zoldhelyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1002\/clc.4960221608-BIB1","first-page":"799","volume-title":"Vascular Medicine","author":"Andrews","year":"1992"},{"key":"10.1002\/clc.4960221608-BIB2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/oxfordjournals.eurheartj.a059467","article-title":"Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death","volume":"10","author":"Davies","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960221608-BIB3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM198405033101801","article-title":"Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death","volume":"310","author":"Davies","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB5","first-page":"157","volume-title":"Molecular Cardiovascular Medicine","author":"Hawiger","year":"1995"},{"key":"10.1002\/clc.4960221608-BIB6","first-page":"115","volume-title":"Molecular Cardiovascular Medicine","author":"Rosenberg","year":"1995"},{"issue":"1","key":"10.1002\/clc.4960221608-BIB7","doi-asserted-by":"crossref","DOI":"10.1016\/0049-3848(96)00035-7","article-title":"The contribution of thrombosis to the clinical expression of coronary atherosclerosis","volume":"82","author":"Davies","year":"1996","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960221608-BIB8","doi-asserted-by":"crossref","first-page":"s7","DOI":"10.1016\/S0140-6736(96)98003-4","article-title":"Coronary thrombosis","volume":"348","author":"Fuster","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB9","first-page":"49","volume-title":"Molecular Cardiovascular Medicine","author":"Gimbrone","year":"1995"},{"key":"10.1002\/clc.4960221608-BIB10","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/01.CIR.91.11.2844","article-title":"Molecular bases of the acute coronary syndromes","volume":"91","author":"Libby","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(97)00157-6","article-title":"Hemostatic risk factors in arterial thrombosis and atherosclerosis: The thrombin-fibrin and platelet-vWF axis","volume":"88","author":"Stormorken","year":"1997","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960221608-BIB12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/106002809502900912","article-title":"Thrombosis and the pharmacology of antithrombotic agents","volume":"29","author":"Haines","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1002\/clc.4960221608-BIB13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM198103193041201","article-title":"Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease","volume":"304","author":"Hirsh","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0002-9149(84)80095-8","article-title":"Conversion from chronic to acute coronary artery disease: Speculation regarding mechanisms","volume":"54","author":"Willerson","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1002\/clc.4960221608-BIB15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.80.1.198","article-title":"Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications","volume":"80","author":"Willerson","year":"1989","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2796.1996.331661000.x","article-title":"Platelet activation mechanisms and markers in arterial thrombosis","volume":"239","author":"Wu","year":"1996","journal-title":"J Intern Med"},{"key":"10.1002\/clc.4960221608-BIB17","first-page":"21","article-title":"The clinical utility of antiplatelet drugs","volume":"XIX","author":"Messmore","year":"1998","journal-title":"Cardiovasc Rev Rep"},{"key":"10.1002\/clc.4960221608-BIB18","first-page":"1.38","volume-title":"Treatment of Heart Diseases","year":"1992","unstructured":"Treatment of Heart Diseases (Eds. WillersonJT, BaimDS, CooleyDA, FrazierOH, GrundySM, KaplanNM, PackerM, SweeneyMS, ZipecDP) p. 1.38-1.60. New York: Gower, 1992"},{"key":"10.1002\/clc.4960221608-BIB19","first-page":"III-100","article-title":"Antithrombotic therapy and progression of coronary artery disease: Antiplatelet vs. antithrombins","volume":"86","author":"Chesebro","year":"1992","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM199203193261205","article-title":"Molecular and cellular biology of blood coagulation","volume":"326","author":"Furie","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0033-0620(97)80035-7","article-title":"Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease","volume":"40","author":"Schussheim","year":"1997","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1002\/clc.4960221608-BIB22","first-page":"3","volume-title":"Thrombosis and Hemorrhage","author":"Schafer","year":"1994"},{"key":"10.1002\/clc.4960221608-BIB23","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1161\/01.CIR.96.9.3233","article-title":"Mechanisms precipitating acute cardiac events: Review and recommendations of an NHLBI workshop","volume":"96","author":"Muller","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archinte.1996.00440120032004","article-title":"Thrombosis in ischemic heart disease","volume":"156","author":"Ambrose","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1002\/clc.4960221608-BIB25","first-page":"III-30","article-title":"Why do plaques rupture?","volume":"86","author":"Falk","year":"1992","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB26","doi-asserted-by":"crossref","first-page":"24C","DOI":"10.1016\/S0002-9149(99)80467-6","article-title":"Elucidation of the role of plaque instability and rupture in acute coronary events","volume":"76","author":"Fuster","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1002\/clc.4960221608-BIB27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1161\/01.ATV.18.11.1707","article-title":"Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques","volume":"18","author":"Johnson","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1002\/clc.4960221608-BIB28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000177335","article-title":"Acute coronary syndromes","volume":"88","author":"Yun","year":"1997","journal-title":"Cardiology"},{"key":"10.1002\/clc.4960221608-BIB29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/01.ATV.18.10.1519","article-title":"Apoptosis in the atherosclerotic plaque: Quantitative and qualitative aspects","volume":"18","author":"Kockx","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1002\/clc.4960221608-BIB30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB31","first-page":"13","article-title":"Conversion from chronic to acute coronary heart disease syndromes: Role of platelets and platelet products","volume":"22","author":"Willerson","year":"1995","journal-title":"Tex Heart Inst J"},{"key":"10.1002\/clc.4960221608-BIB32","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/01.CIR.92.9.2373","article-title":"Blockade of platelet GPIIb\/IIIa receptors as an antithrombotic strategy","volume":"92","author":"Coller","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/j.1875-9114.1998.tb03890.x","article-title":"Advancing the battle against acute ischemic syndromes: A focus on the GPIIb\/IIIa inhibitors","volume":"18","author":"Dobesh","year":"1998","journal-title":"Pharmacother"},{"key":"10.1002\/clc.4960221608-BIB34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1642723","article-title":"Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists","volume":"74","author":"Harker","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1002\/clc.4960221608-BIB35","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB36","first-page":"1287","article-title":"Aspirin as an antiplatelet drug","volume":"3","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.CIR.97.2.211","article-title":"Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence","volume":"97","author":"Topol","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB38","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2165\/00003495-199549060-00002","article-title":"Novel antithrombotic drugs in development","volume":"49","author":"Verstraete","year":"1995","journal-title":"Drugs"},{"key":"10.1002\/clc.4960221608-BIB39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0165-6147(92)90126-Q","article-title":"Development of GP IIb\/IIIa antagonists and antithrombotic agents","volume":"13","author":"Nichols","year":"1992","journal-title":"Trends Pharmacol Sci"},{"key":"10.1002\/clc.4960221608-BIB40","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/S0021-9258(18)61290-6","article-title":"Protein sequence of endothelial glycoprotein Illa derived from a cDNA clone","volume":"262","author":"Fitzgerald","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1002\/clc.4960221608-BIB41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.2420006","article-title":"Platelet membrane glycoprotein GPIIb\/IIIa: Member of a family of Arg-Gly-Asp specific adhesion receptors","volume":"231","author":"Pytela","year":"1986","journal-title":"Science"},{"key":"10.1002\/clc.4960221608-BIB42","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0002-8703(98)70297-2","article-title":"An overview of the results of clinical trials with glycoprotein IIb\/IIIa inhibitors","volume":"135","author":"Adgey","year":"1998","journal-title":"Am Heart J"},{"key":"10.1002\/clc.4960221608-BIB43","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"The EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: Results at six months","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long-term protection from myocardial ischemic events in a randomized trial of brief integrin b\u03033 blockade with percutaneous coronary intervention","volume":"278","author":"Topol","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960221608-BIB46","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"The EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study","volume":"349","author":"The CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"The EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"The RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB51","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB52","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB53","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","article-title":"Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina: The Canadian Lamifiban Study","volume":"94","author":"Th\u00e9roux","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB54","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina","volume":"97","author":"The PARAGON Investigators","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB55","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.CIR.98.13.1268","article-title":"Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb\/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial","volume":"98","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB56","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/S0002-8703(98)70239-X","article-title":"Long-term administration of glycoprotein IIb\/IIIa antagonists","volume":"135","author":"Quinn","year":"1998","journal-title":"Am Heart J"},{"key":"10.1002\/clc.4960221608-BIB57","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/01.CIR.90.6.2976","article-title":"Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand-glycoprotein lb binding domain","volume":"90","author":"McGhie","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB58","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/01.CIR.89.6.2822","article-title":"Blockade of platelet membrane glycoprotein lb receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs","volume":"89","author":"Yao","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0038-1656050","article-title":"Inhibition of leukocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury","volume":"77","author":"Golino","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1002\/clc.4960221608-BIB60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/01.ATV.12.4.430","article-title":"Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase","volume":"12","author":"Mills","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1002\/clc.4960221608-BIB61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The antiplatelet effects of ticlopidine and clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1002\/clc.4960221608-BIB62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0049-3848(92)90206-P","article-title":"Ticlopidine and platelet function in healthy volunteers","volume":"65","author":"Dembinska Kiec","year":"1992","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960221608-BIB63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.RES.70.1.39","article-title":"ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries","volume":"70","author":"Yao","year":"1992","journal-title":"Circ Res"},{"issue":"36","key":"10.1002\/clc.4960221608-BIB65","first-page":"H488","article-title":"Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis","volume":"267","author":"Yao","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1002\/clc.4960221608-BIB66","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB67","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/clc.4960221608-BIB68","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1177\/106002809202601211","article-title":"Hirudins: Antithrombin anticoagulants","volume":"26","author":"Stringer","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1002\/clc.4960221608-BIB69","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(94)90032-9","article-title":"The development of hirudin as an antithrombotic drug","volume":"74","author":"Markwardt","year":"1994","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960221608-BIB71","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1073\/pnas.83.4.1084","article-title":"Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis","volume":"83","author":"Harvey","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/clc.4960221608-BIB72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-2007-1002592","article-title":"The comeback of hirudin as an antithrombotic agent","volume":"17","author":"Markwardt","year":"1991","journal-title":"Semin Thromb Haemost"},{"key":"10.1002\/clc.4960221608-BIB73","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","author":"The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB74","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB75","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","article-title":"Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial infarction without ST elevation: A pilot study","volume":"96","author":"Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty","volume":"333","author":"Serruys","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB77","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960221608-BIB78","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","article-title":"Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty","volume":"87","author":"Topol","year":"1993","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB79","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.89.4.1567","article-title":"A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction","volume":"89","author":"Lid\u00f3n","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB80","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2036.1997.153328000.x","article-title":"Platelets in inflammatory bowel disease-pathogenic role and therapeutic implications","volume":"11","author":"Collins","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/clc.4960221608-BIB81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2036.1997.154330000.x","article-title":"Review article: COX-II inhibitors-a new generation of safer NSAIDs?","volume":"11","author":"Donnelly","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/clc.4960221608-BIB82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0889-8553(05)70252-1","article-title":"Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract","volume":"25","author":"Masferrer","year":"1996","journal-title":"Gastroenterol Clin N A"},{"key":"10.1002\/clc.4960221608-BIB83","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1007\/s000110050287","article-title":"Cyclooxygenase-2 as a therapeutic target","volume":"47","author":"Mitchell","year":"1998","journal-title":"Inflamm Res"},{"key":"10.1002\/clc.4960221608-BIB84","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.CIR.95.3.715","article-title":"A tissue plasminogen activator\/P-selectin fusion protein is an effective thrombolytic agent","volume":"95","author":"Fujise","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB85","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/359848a0","article-title":"Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets","volume":"359","author":"Palabrica","year":"1992","journal-title":"Nature"},{"key":"10.1002\/clc.4960221608-BIB86","unstructured":"Zoldhelyi P, Beck PJ, Akhtar S, Ober JC, Bjencke R, Ahmed M, McNatt J, Clubb FC, Yeh ETH, Willerson JT: Prevention of coronary thrombosis after arterial injury by selectin inhibition. 1999 (submitted)"},{"key":"10.1002\/clc.4960221608-BIB87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.CIR.93.1.10","article-title":"Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene","volume":"93","author":"Zoldhelyi","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/clc.4960221608-BIB88","unstructured":"Zoldhelyi P, McNatt J, Ober JC, Shelat HS, Dillard PM, Wun T-C, Willerson JT: Gene transfer of human tissue factor inhibitor in vitro and to severely atherosclerotic arteries in vivo. 1999 (submitted)"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960221608","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/clc.4960221608\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:18:14Z","timestamp":1710490694000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960221608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":88,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[1999,8]]}},"URL":"https:\/\/doi.org\/10.1002\/clc.4960221608","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}